Novel genes and markers in type 2 diabetes and obesity

Abstract

Genes, SNP markers and haplotypes of susceptibility or predisposition to T2D and subdiagnosis of T2D and related medical conditions are disclosed. Methods for diagnosis, prediction of clinical course and efficacy of treatments for T2D, obesity and related phenotypes using polymorphisms in the risk genes are also disclosed. The genes, gene products and agents of the invention are also useful for monitoring the effectiveness of prevention and treatment of T2D and related traits. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of T2D. Novel methods for prevention and treatment of metabolic diseases such as T2D based on the disclosed T2D genes, polypeptides and related pathways are also disclosed.

1 . A method for determining an increased risk of type 2 diabetes, in a human subject comprising:
 a) providing a biological sample taken from the subject; and   b) testing the sample for the presence of the A allele at position rs1535435 in said sample,   wherein the presence of the A allele is associated with an increased risk of type 2 diabetes.   
     
     
         2 . The method according to  claim 1 , further comprising testing the sample for the presence of at least one of the alleles selected from the group consisting of the A allele at position rs6712932, the A allele at position rs9494266, the A allele at position rs942740 and the A allele at position rs1749718. 
     
     
         3 . The method according to  claim 1 , further comprising testing the sample for the presence of at least one of the alleles selected from the group consisting of the A allele at position rs2591797, the A allele at position rs7002832, the G allele at position rs911946, the G allele at position rs12531570, the A allele at position rs10151259, the A allele at position rs4383389, the A allele at position rs7581414, the A allele at position rs4446815 and the C allele at position rs4417767.